Amylyx Pharmaceuticals Jumps 45% as Trial Cuts Hypoglycemia by 55%

NEW YORK, August 18 —

Amylyx Pharmaceuticals, Inc. (AMLX) surged 45% in a single session after trial data showed its experimental drug cut dangerous hypoglycemia events by 55%.

55% Is a Clinically Meaningful Threshold, Not an Incremental Win

Severe hypoglycemia, the kind that requires outside assistance or results in loss of consciousness, is one of the most feared and costly complications in insulin-treated patients. A drug that cuts these events by more than half does not just improve a metric on a slide deck: it addresses a population that has already cycled through existing options. Regulators reward this magnitude of efficacy with expedited review pathways, which compresses the distance to commercialization. When data moves this cleanly, a single-day repricing of that magnitude is not noise.

The 15.6% Short Float That Turned Good Data Into the Surge

Before Monday, 15.6% of AMLX's float was sold short. When a binary catalyst lands on the right side of that position, covering is not optional. The gap-up is visible in the chart. The surge reflects genuine clinical conviction, but it also reflects short sellers who had no exit. Investors who entered after the open paid a blended price that includes squeeze premium alongside efficacy enthusiasm. That distinction matters when the next data readout either confirms or challenges that figure in a larger cohort.

HC Wainwright Goes to $55: What That Price Needs to Be Right

HC Wainwright raised its price target to $55.00 against Monday's close of $33.88, a 62% additional upside call from a firm that had just watched the stock gap that far. That is not a cautious read. It prices in a clean FDA interaction, a priority or breakthrough designation, and a commercial launch path for a drug still in trials. The raise signals confidence that the efficacy figure is durable. Whether it holds in a larger, more diverse patient cohort is the question the next readout will answer.

The $77mn FCF Burn and Why the FDA Timeline Is the Only Clock That Matters

Amylyx burned $77mn in free cash flow over the trailing period and reported EPS of -$1.41. A forward P/E of -24.4x is not a valuation: it is a countdown. For a company pivoting its pipeline beyond ALS, every quarter of burn narrows the window before clinical milestones must convert to capital events. Use the DCF calculator to stress-test the $55 target against different runway assumptions: the cash burn and the analyst price target pull in opposite directions. The thesis breaks on one number. If the hypoglycemia reduction does not replicate in the next confirmatory study, Monday's gains reverse and the burn rate becomes the story.

For the full Amylyx fundamental picture, including cash position, pipeline risk, and valuation comps, generate a Basis Report at AMLX's stock page.

Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.